Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06741436 · ClinicalTrials.gov registry record

Exercise Testing After Preeclampsia

A clinical trial of Hypertension and Preeclampsia, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT06741436: Recruiting study of Hypertension and Preeclampsia, sponsored by Vanderbilt University Medical Center.

NCT06741436 is a study of Hypertension and Preeclampsia that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 500 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06741436, a study of Hypertension and Preeclampsia, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

Though cardiovascular disease (CVD) is the leading cause of mortality in women, traditional epidemiology in this area has focused on later life, when cardiometabolic risk has already exacted a cumulative toll on the vascular system. Recent data from the investigators and others has highlighted pregnancy as a unique, early moment of cardiovascular stress in young women that may "unmask" CVD propensity. It is unclear if PreE simply represents a "failed stress test" or directly contributes to the pathophysiology of future CVD. While mechanistic studies have largely been the purview of model-based studies, endothelial dysfunction has emerged as central to the pathogenesis of both PreE and peripartum cardiac dysfunction. Indeed, biomarkers of endothelial dysfunction and angiogenic imbalance during pregnancy have been shown to remain elevated at least 6 months post-partum. Moreover, peri-partum endothelial dysfunction can persist for years post-delivery and remains a significant risk factor for CVD (even after adjustment for other traditional risk factors). While these findings suggest that PreE-associated endothelial dysfunction and inflammation may contribute to early myocardial dysfunction that presages HF risk decades before its onset, the modifiable epidemiology of PreE-associated LVDD, including potential mechanisms of risk, remains unclear, limited by lack of precision molecular phenotypes accessible in a large number of American women across race. Ultimately, understanding the epidemiology and pathobiology of PreE-associated myocardial dysfunction affords a unique opportunity to identify women at risk with a longer lead-time for risk factor modification to interrupt CVD. The investigators hypothesize that persistent structural-functional myocardial alterations after PreE are linked to pre- and post-gravid cardiometabolic risk factors (SA1), functional and hemodynamic impairment (SA2) and select pathways of vascular and inflammatory stress relevant to HF risk (SA3

Primary Outcome

Pre-pregnancy risk factors (HTN, DM, delivery body mass index \[BMI\], age), pregnancy-specific risk factors (PreE severity, gestational age at delivery, gravidity, GDM, SGA) and PP risk factors (weight change, median systolic BP 0-2 weeks PP, resting BP at study visit) will be measured. Ordinary least squares (OLS) regressions will be used to estimate the relationship between Lateral E/e' at 52 weeks and the above risk factors, adjusting for baseline values, to determine if the diastolic functi

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-02-18
Est. Completion 2029-06-30

What NCT06741436 shows while recruiting

NCT06741436 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 0 interventions.

NCT06741436 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT06741436 about?

NCT06741436 is a clinical study titled "Exercise Testing After Preeclampsia". Though cardiovascular disease (CVD) is the leading cause of mortality in women, traditional epidemiology in this area has focused on later life, when cardiometabolic risk has already exacted a cumulative toll on the vascular system. Recent data from the investigators and others has highlighted pregn...

What is the current status of trial NCT06741436?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-02-18. Estimated completion is 2029-06-30.

What conditions does trial NCT06741436 study?

This clinical trial studies the following conditions: Hypertension, Preeclampsia, Heart Failure Preserved Ejection Fraction.

Who is sponsoring clinical trial NCT06741436?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06741436 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06741436's enrollment target sits among peer trials

500 116th of 470 higher than 349 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06741436, the US trial registry maintained by the National Library of Medicine. NCT06741436 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.